Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 12/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | FABP3 | P05413 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.46 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008431 | 0.95 | ADORA1 (0.62) | ADORA1ADORA3GFERFABP3FABP4 | |
| SCHEMBL5011987 | 0.95 | ADORA1 (0.66) | ADORA1ADORA3GFERFABP3FABP4 | |
| SCHEMBL5008553 | 0.94 | ADORA1 (0.59) | ADORA1ADORA3GFERDHODHMAPT | |
| SCHEMBL5005264 | 0.93 | GFER (0.55) | ADORA1ADORA3GFERFABP4MAPT | |
| SCHEMBL5007722 | 0.92 | ADORA1 (0.70) | ADORA1ADORA3GFERFABP3FABP4 | |
| SCHEMBL5008399 | 0.91 | ADORA1 (0.55) | ADORA1ADORA3GFERDHODHMAPT | |
| SCHEMBL5010557 | 0.91 | ADORA1 (0.71) | ADORA1ADORA3GFERFABP3FABP4 | |
| SCHEMBL5008382 | 0.89 | ADORA1 (0.62) | ADORA1ADORA3GFERFABP3FABP4 | |
| SCHEMBL5008535 | 0.87 | ADORA1 (0.53) | ADORA1ADORA3GFERDHODHMAPT | |
| SCHEMBL5008505 | 0.85 | GFER (0.62) | ADORA1ADORA3GFERMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | claimed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | claimed |
| EP-1567517-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | Bayer Pharmaceuticals Corporation (US) | 2005-08-31 | — | — | EP | claimed |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | claimed |
| WO-2004050651-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-17 | — | — | WO | claimed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | ADORA1 749/4885ADORA3 111/4885GFER 1604/4885 |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | ADORA1 749/4885ADORA3 111/4885GFER 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.